Published in Lab Law Weekly, August 3rd, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Novartis Pharmaceuticals Corporation.
Report 1: Patients with osteoarthritis who also have controlled hypertension experienced a slight decrease in average daily blood pressure when treated with the investigational selective COX-2 inhibitor lumiracoxib compared to a slight increase in those taking ibuprofen, a commonly-used non-steroidal anti-inflammatory drug (NSAID).
These new results, presented today at the Annual European Congress of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly